Buteyko Method

Accounts of the originator

The history page of the Buteyko Breathing Association, a practitioner organisation, states that Konstantin Buteyko (1923-2003) was born near Kyiv, enrolled as a medical student in Moscow in 1946, and was assigned to record patients' breathing rates against the severity of their illness. It reports that he concluded hyperventilation was associated with poor outcomes. A Danish training centre dates his key observation to 1953. Both are accounts written by organisations that teach the method, and neither has been checked here against archival or biographical scholarship.

The association says that, drawing on yoga texts, he experimented on himself and on patients, that colleagues were sceptical, and that he was eventually permitted to continue research in a Siberian laboratory. The pages reviewed give no dates for this work, so they do not establish when the method took its present form, and no independent source reviewed examines the claimed link to yoga texts.

Reported recognition and international spread

The same page states that Soviet authorities approved a formal trial in asthmatic children in Moscow in the early 1980s and then approved wider use. It adds that in the late 1980s a New Zealand businessman met the technique in Russia and arranged for a Russian teacher to visit New Zealand, from where it spread to Australia, and that the first blinded controlled trial took place in Australia in 1994. No trial report or official record for these statements was located, so they remain unverified practitioner history.

A programme rather than a single protocol

A 2005 review noted that only four clinical trials and two conference abstracts of the technique had been published by then. It described the technique as a complex package that also includes advice and education about medication use, nutrition, exercise and general relaxation, and as not being a standardised treatment. Modern courses should therefore not be assumed to match the original teaching or one another.

Names in use

Buteyko Breathing Technique (BBT), Buteyko method and Buteyko breathing appear interchangeably in the trial literature reviewed. Individual reports describe the exercises differently, for example as eucapnic Buteyko breathing in one trial and as breathing exercises focusing on shallow nasal breathing in another. The labels refer to a family of teaching programmes, not to one fixed protocol.

Control pause and hyperventilation

In one trial report, the control pause is the time a person can comfortably hold the breath after a normal exhalation. The report states that, within the theory, a longer pause is supposed to correspond to higher carbon dioxide (CO2) in the blood. In the same report, hyperventilation means hidden, chronic over-breathing, such as mouth breathing and mainly chest breathing, not an acute panic episode. These are the theory's definitions and are not established clinical measures.

Research on breathing exercises also uses the Nijmegen Questionnaire to score symptoms attributed to hyperventilation. A Cochrane review reported it as a secondary outcome alongside asthma quality of life, which separates the questionnaire result from the theory that over-breathing drives asthma.

Related breathing programmes

National guidance groups the Buteyko method with the Papworth method as behavioural programmes centred on breathing exercises and techniques to reduce dysfunctional breathing. The Cochrane review lists yogic breathing and deep diaphragmatic breathing alongside them. These programmes share some elements but are not equivalent, and results for one should not be assumed for another.

Teaching format

National guidance describes these programmes as instruction by a trained therapist in exercises to reduce respiratory rate and minute volume and to promote nasal, diaphragmatic breathing. It adds that trials with more than five hours of intervention appeared more likely to be effective. In a 2024 German trial the course was a five-day group course of 90 minutes a day and a booster session a week later, followed by home practice twice daily for 20 minutes over three months, with adherence recorded.

Other trials used different formats. One taught the exercises from instructional videos, with practice twice daily and when needed for symptom relief over 30 weeks, and another asked adults to practise at home twice daily for six months. Course length, delivery and practice schedules therefore vary widely.

Components

Described elements include nasal breathing, reduced breathing and breath holding after exhalation, with participants recording their control pause. At night the technique is described as encouraging mouth taping, and a crossover trial tested microporous tape in that way. The programme as a whole also includes advice about medication use, nutrition and exercise, and relaxation.

Questions a participant can ask

The sources reviewed do not describe what a participant typically feels during practice, so this article makes no statement about it. A person considering a course can ask how long it lasts, what daily practice is expected, whether the teacher has medical or physiotherapy training, and how the course relates to prescribed medicines. Participation is voluntary and a person can stop at any point.

What proponents hold

A Danish training centre states that Buteyko concluded that hidden hyperventilation was the primary cause of asthma and many other diseases, and that the method eliminates it. The Buteyko Breathing Association describes the same link between over-breathing and poor health. These are the claims of the organisations that teach it. They go beyond what the studies below tested, and no source reviewed tests them.

Uses that have been studied

Research has concentrated on adults with asthma, with outcomes such as asthma-related quality of life, symptom scores, use of reliever (bronchodilator) and inhaled corticosteroid medication, and lung function. A 2005 review described the carbon dioxide theory as relating CO2 levels to airway calibre. The sources reviewed give no controlled evidence for other conditions, so any other uses are claims only.

Guideline positions

The British guideline (SIGN 158, November 2024 edition, corrections May 2025) states that behavioural breathing programmes, including the Papworth and Buteyko methods, can lead to modest improvements in asthma symptoms and quality of life and reduce bronchodilator need in adults, with little effect on lung function or airway inflammation. It recommends that breathing exercise programmes can be offered to adults with asthma as an adjuvant to pharmacological treatment, and finds insufficient evidence for children aged 12 and under.

The 2025 Global Initiative for Asthma (GINA) report says breathing exercises may be considered a supplement for symptoms and quality of life but do not improve lung function or reduce exacerbation risk. It notes that perceived improvement may be largely due to relaxation, reduced reliever use or patient engagement. Both documents address breathing exercises generally and are not specific endorsements of the Buteyko method.

Systematic reviews

A 2020 Cochrane review of 22 trials in 2,880 adults with mild to moderate asthma included only two Buteyko trials, against fourteen of yoga. Breathing exercises improved quality of life at three months (mean difference 0.42, moderate certainty), but results for asthma control and lung function were inconclusive, and adverse effects were not assessed.

A 2026 meta-analysis of seven randomised trials comparing the technique plus standard care with standard care alone found better asthma control (standardised mean difference -0.33, 95% CI -0.54 to -0.13) but no overall quality-of-life benefit, with a benefit in children and adolescents. The authors call the evidence limited. Comparison with standard care alone cannot separate technique-specific effects from attention and expectation.

Individual randomised trials

In a 2003 trial of 90 adults taking inhaled corticosteroids (69 completed), the Buteyko group had lower symptom scores and used about two fewer reliever puffs a day at six months than a placebo-device group, without differences in lung function, bronchial responsiveness, exacerbations or steroid reduction. In a 2008 trial against physiotherapist-led breathing and relaxation, asthma control at six months rose from 40% to 79% against 44% to 72%, with a larger inhaled steroid reduction in the Buteyko group.

A double-blind 2006 trial in 57 adults compared shallow nasal breathing with non-specific upper body exercises over 30 weeks and found no clinically important between-group differences, although reliever use fell 86% and steroid dose 50% in both groups. A 2024 trial of 60 adults reported improved control pause, symptom scores and about 20% less medicine use against usual therapy, with no attention control and retrospective registration.

The hyperventilation hypothesis

The 2005 review called the theory linking carbon dioxide to airway calibre attractive and partly based on experimental studies, but stated that it is not known whether changed breathing patterns can raise CO2 significantly. It found insufficient evidence that this is how any effect arises. A later review states that low CO2 and over-breathing are linked to bronchoconstriction and symptoms in asthma, while calling evidence for related theories in panic disorder inconclusive.

Non-specific effects

The double-blind trial that compared contrasting exercises reported that both groups improved equally, and its authors attributed improvement to the routine of practising and to relaxation, self-efficacy and delaying reliever use, not to the exercise type. GINA draws the same inference and says such studies are only high quality when contact with healthcare providers is matched. Many Buteyko trials used usual care as the comparator.

Components tested alone

A randomised single-blind crossover study of 51 adults with symptomatic asthma tested night-time mouth taping, a feature of Buteyko teaching, for four weeks. It found no difference from usual breathing in morning peak flow or symptom scores. This tests one component only and says nothing about the full programme.

Reported adverse events

The 2026 meta-analysis reported no adverse events in the included trials, and the 2024 trial recorded none apart from a hospital admission for sinusitis and otitis media in the usual-therapy group. In the 2006 trial, 259 other adverse events were reported, none judged related to treatment. The Cochrane review did not assess adverse effects. Not reporting harms is not evidence that none occur.

Medication and care boundaries

The British guideline positions breathing programmes as an adjuvant to pharmacological treatment and says they should ideally be part of integrated medical care. GINA says they do not reduce exacerbation risk. Reductions in medicine use in trials occurred within study protocols with outcomes measured; the 2006 trial attempted steroid reduction in planned steps. This should not be read as guidance to change prescribed treatment, which is a decision for a person's clinician.

The British guideline advises referral to hospital for features of acute severe or life-threatening asthma. Breathing practice is not a replacement for assessment, prescribed treatment or emergency care.

Suitability and training

The Cochrane review covered outpatients with mild to moderate asthma, and the 2024 trial authors note that people with severe asthma were not studied. The British guideline found insufficient evidence in children aged 12 and under. The sources reviewed do not describe training standards, professional registers or protected titles for teachers of the method, and no statutory regulation was found.